Studies on the pharmacological control of hyperlipemia in experimental nephrotic syndrome.
D000818:Animals; D002087:Butyrates / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008074:Lipoproteins; D008099:Liver / Q000187:drug effects; D009404:Nephrotic Syndrome / Q000097:blood / Q000139:chemically induced; D009705:Nucleosides; D009929:Organ Size; D010713:Phosphatidylcholines / Q000097:blood; D010743:Phospholipids / Q000097:blood; D011422:Propionates / Q000627:therapeutic use; D011691:Puromycin; D051381:Rats; D013974:Thyroxine / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D002087:Butyrates; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D009705:Nucleosides; D010713:Phosphatidylcholines; D010743:Phospholipids; D011422:Propionates; D014280:Triglycerides; D002792:Cholestyramine Resin; D011691:Puromycin; D002784:Cholesterol; D013974:Thyroxine